Call for Abstract

5th International Conference and Exhibition on Cell and Gene Therapy, will be organized around the theme “Frontiers in Cell and Gene Therapy: From Bench to Bedside”

Cell Therapy 2016 is comprised of 20 tracks and 118 sessions designed to offer comprehensive sessions that address current issues in Cell Therapy 2016.

Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.

Register now for the conference by choosing an appropriate package suitable to you.

Gene therapy and cell therapy are overlapping fields of biomedical research with the goals of repairing the direct cause of genetic diseases in the DNA or cellular population, respectively. The development of suitable gene therapy treatments for many genetic diseases and some acquired diseases has encountered many challenges and uncovered new insights into gene interactions and regulation. Further development often involves uncovering basic scientific knowledge of the affected tissues, cells, and genes, as well as redesigning vectors, formulations, and regulatory cassettes for the genes. Cell therapy is expanding its repertoire of cell types for administration. Cell therapy treatment strategies include isolation and transfer of specific stem cell populations, administration of effector cells, and induction of mature cells to become pluripotent cells, and reprogramming of mature cells.

Related Conferences: International Conference on Clinical And Molecular Genetics, 28-30 November 2016 (Chicago, USA); 6th International Conference on Genomics & Pharmacogenomics, 22-24 September 2016 (Berlin, Germany); World Congress on Human Genetics, 31 October – 02 November 2016 (Valencia, Spain); International Conference on Genetic Counselling And Genomic Medicine, 11-12 August, 2016 (Birmingham, UK); 2nd Cell & Gene Therapy Conference 9-10 September 2015 (Philadelphia, United States); 2015 Midwest Conference on Cell Therapy & Regenerative Medicine September 18-19 2015 (Kansas City, Missouri); 5th Cell & Gene Therapy Conference 19-21 May 2016 (San Antonio, United States); Cell & Gene Therapy Europe 29-30 September 2015 (Barcelona, Spain); Cell Manufacturing and  Gene Therapy Congress 2015 2-3 December 2015 (Brussels, Belgium). 

  • Track 1-1Somatic gene therapy
  • Track 1-2Gene therapy for down syndrome
  • Track 1-3Haemophilia gene therapy
  • Track 1-4Antisense gene therapy
  • Track 1-5Applications of gene therapy
  • Track 1-6Advantages & disadvantages of gene therapy
  • Track 1-7Adinovirus therapy
  • Track 1-8Gene replacement therapy
  • Track 1-9Exvivo gene therapy
  • Track 1-10Germline gene therapy
  • Track 1-11Gene therapy for color blindness

Articles containing or consisting of human cells or tissues that are intended for implantation, transplantation, infusion, or transfer to a human recipient. Gene therapies are novel and complex products that can offer unique challenges in product development. Hence, ongoing communication between the FDA and stakeholders is essential to meet these challenges. Gene therapy products are being developed around the world, the FDA is engaged in a number of international harmonization activities in this area.

Examples: Musculoskeletal tissue, skin, ocular tissue, human heart valves; vascular graft, dura mater, reproductive tissue/cells, Stem/progenitor cells ,somatic cells, Cells transduced with gene therapy vectors , Combination products (e.g., cells or tissue + device)

Related conferences: International Conference on Clinical And Molecular Genetics, 28-30 November 2016 (Chicago, USA); 6th International Conference on Genomics & Pharmacogenomics, 22-24 September 2016 (Berlin, Germany); World Congress on Human Genetics, 31October – 02November 2016 (Valencia, Spain); International Conference on Genetic Counselling And Genomic Medicine, 11-12 August, 2016 (Birmingham, UK); Cell & Gene Therapy Congress, 19-21 May 2016 ( San Antonio, USA); 2015 Midwest Conference on Cell Therapy & Regenerative Medicine September 18-19 2015 (Kansas City, Missouri); 2nd Cell & Gene Therapy Conference 9-10 September 2015 (Philadelphia, United States); Cell & Gene Therapy Europe 29-30 September 2015 (Barcelona, Spain); Cell Manufacturing and  Gene Therapy Congress 2015 2-3 December 2015 (Brussels, Belgium). 

  • Track 2-1Cellular immuno therapy products
  • Track 2-2Cellular & gene therapy products
  • Track 2-3Allogeneic & autologous therapy products
  • Track 2-4Cell based therapy products
  • Track 2-5Tissue based products

Cellular therapy, also called live cell therapy, cellular suspensions, glandular therapy, fresh cell therapy, sick cell therapy, embryonic cell therapy, and organotherapy - refers to various procedures in which processed tissue from animal embryos, fetuses or organs, is injected or taken orally. Products are obtained from specific organs or tissues said to correspond with the unhealthy organs or tissues of the recipient. Proponents claim that the recipient's body automatically transports the injected cells to the target organs, where they supposedly strengthen them and regenerate their structure. The organs and glands used in cell treatment include brain, pituitary, thyroid, adrenals, thymus, liver, kidney, pancreas, spleen, heart, ovary, testis, and parotid. Several different types of cell or cell extract can be given simultaneously - some practitioners routinely give up to 20 or more at once.

Related Conferences: International Conference on Clinical And Molecular Genetics, 28-30 November 2016 (Chicago, USA); 6th International Conference on Genomics & Pharmacogenomics, 22-24 September 2016 (Berlin, Germany); World Congress on Human Genetics, 31October – 02November 2016 (Valencia, Spain); International Conference on Genetic Counselling And Genomic Medicine, 11-12 August, 2016 (Birmingham, UK); Cell & Gene Therapy Congress, 19-21 May 2016 ( San Antonio, USA); Adaptive T cell Therapy 27-28 April, 2016 ( Boston, MA); 2ND International Congress on Stem Cell and Cellular Therapies 15-18 October 2015 (Antalya, Turkey); Cellular Therapy Today 9-12 September 2015 (Manchester,UK); The 2nd Gene and Immunotherapy Conference in Vietnam 25-26 September 2015 (Ho Chi Minh City, Vietnam); Cell and Gene Therapy  World 25- 16 January 2016 (Washington DC).

  • Track 3-1Role of molecular markers in therapies
  • Track 3-2Target tissues & routes of delivery
  • Track 3-3Causes of regenerative failure
  • Track 3-4Potential uses of defined cell population
  • Track 3-5Programming cell fate
  • Track 3-6Cell replacement therapy

Cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecules ("molecular targets") that are involved in the growth, progression, and spread of cancer. Many cancer therapies have been approved by the Food and Drug Administration (FDA) to treat specific types of cancer. The development of targeted therapies requires the identification of good targets that is, targets that play a key role in cancer cell growth and survival. One approach to identify potential targets is to compare the amounts of individual proteins in cancer cells with those in normal cells.  Proteins that are present in cancer cells but not normal cells or that are more abundant in cancer cells would be potential targets, especially if they are known to be involved in cell growth or survival.

Related Conferences: International Conference on Cervical Cancer, 22-23 September, 2016 (Vienna, Austria); 6th World Congress on Cancer Therapy, 01-03 December, 2016 (Baltimore, USA); 13th Global Summit on Cancer Therapy 17-19 October, 2016 (Dubai, UAE); International Conference on Pancreatic and Colorectal Cancer, 29-30 March, 2016 (Atlanta, USA); Global Summit on Melanoma And Carcinoma, 14-15 July, 2016 (Brisbane, Australia); Chromatin and Epigenetic in Cancer ( Atlanta, Georgia); Advances in Ovarian Cancer Research: Exploiting Vulnerabilities (Orlando, Florida); Advance in Breast Cancer Research ( Washington, DC); Advances in Pediatric Cancer Research (Florida);  New Horizons in Cancer Research Conference (Sanghai, China).

  • Track 4-1Gene therapy in cancer
  • Track 4-2Therapeutics cancer vaccines
  • Track 4-3Genetically engineered cancer vaccines
  • Track 4-4Genomic & cancer drug resistance
  • Track 4-5Modern approaches in molecular cancer therapeutics
  • Track 4-6Cell cycle & oncology
  • Track 4-7Characteristics of cancer cells
  • Track 4-8Pancreatic cancer gene therapy
  • Track 4-9Prostate cancer gene therapy
  • Track 4-10Lung cancer gene therapy
  • Track 4-11Breast cancer gene therapy
  • Track 4-12Challenges & risks of cancer gene therapy

Nano Therapy may be defined as the monitoring, repair, construction and control of human biological systems at the molecular level, using engineered nanodevices and nanostructures. Basic nanostructured materials, engineered enzymes, and the many products of biotechnology will be enormously useful in near-term medical applications. However, the full promise of nanomedicine is unlikely to arrive until after the development of precisely controlled or programmable medical nanomachines and nanorobots.

Related Conferences: 2nd International Conference and Expo On Computer Graphics & Animation, 21-22 September, 2015 (San Antonio, USA); 4th International Conference and Exhibition On Biosensors & Bioelectronics, 28-30 September, 2015 (Atlanta, USA); 3rd International Conference and Exhibition On Mechanical & Aerospace Engineering, 05-07 October, 2015 (San Antonio, USA); Global Summit on Electronics and Electrical Engineering, 03-05 November, 2015 (Valencia, Spain); International Conference on Medical Devices, 21-22 September, 2015(Florida, USA); Nanotechnologies in Drug Delivery  Congress 27-28 April 2016  (London, UK); 4th Annual Symposium on Nanobiotechnology 7-8 October 2015 (Germany); Radiation Damage in biomolecular Systems: Nanoscale Insights into Ion-Beam Cancer Therapy 20-24 may 2016 (Germany); 5th International Conference Nanomaterials: Applications & Properties 2015, 16-23 September 2015 (Lviv, Ukraine); International Conference on Micro-and Nano-Engineering 2015, 21-24 September2015, (The Hague, Netherlands).

  • Track 5-1Nano methods to target cancer cells
  • Track 5-2Nano micro fluids in cell therapy
  • Track 5-3Nano materials and nano engineering
  • Track 5-4Nano vaccines
  • Track 5-5Pros & cons of molecular manufacturing

Stem cells have newly become a huge catchphrase in the skincare biosphere. Skincare specialists are not using embryonic stem cells; it is impossible to integrate live materials into a skincare product.  Instead, scientists are creating products with specialized peptides and enzymes or plant stem cells which, when applied topically on the surface, help to protect the human skin stem cells from damage and deterioration or stimulate the skins own stem cells. Currently, the technique is mainly used to save the lives of patients who have third degree burns over very large areas of their bodies

Related Conferences: 8th Indo Global Summit And Expo On Vaccines, Therapeutics & Healthcare, 02-04 November, 2015, (Hyderabad, India); 4th International Conference On Clinical Microbiology And Microbial Genomics, 05-07 October, 2015 (Philadelphia, USA); International Conference On Psoriasis, 28-30 November, 2016 (Baltimore, USA); 6th International Conference On Clinical And Experimental Dermatology, 05-07, May, 2016 (Chicago, USA); 11th Global Dermatologists Meeting, 14-16, November, 2016 (Dubai, UAE); 2nd International Conference And Exhibition On Cosmetic Dermatology &Haircare, 05-06, December, 2016 (Seattle, USA); Adaptive T cell Therapy 27-28 April, 2016 ( Boston, MA), 2ND International Congress on Stem Cell and Cellular Therapies 15-18 October 2015 (Antalya, Turkey); Cellular Therapy Today 9-12 September 2015 (Manchester,UK); Cell and Gene Therapy  World 25- 16 January 2016 (Washington DC). 

  • Track 6-1Adipose derived stem cells
  • Track 6-2Hair follicle cells
  • Track 6-3Blood stem cells
  • Track 6-4Skin grafting
  • Track 6-5Human somatic cells

Highly active antiretroviral therapy dramatically improves survival in HIV-infected patients. However, persistence of HIV in reservoirs has necessitated lifelong treatment that can be complicated by cumulative toxicities, incomplete immune restoration, and the emergence of drug-resistant escape mutants. Cell and gene therapies offer the promise of preventing progressive HIV infection by interfering with HIV replication in the absence of chronic antiviral therapy.

Related Conferences: International Conference on Clinical And Molecular Genetics, 28-30 November 2016 (Chicago, USA); 6th International Conference on Genomics & Pharmacogenomics, 22-24 September 2016 (Berlin, Germany); World Congress on Human Genetics, 31 October – 02 November 2016 (Valencia, Spain); International Conference on Genetic Counselling And Genomic Medicine, 11-12 August, 2016 (Birmingham, UK); 2nd Cell & Gene Therapy Conference 9-10 September 2015 (Philadelphia, United States); 2015 Midwest Conference on Cell Therapy & Regenerative Medicine September 18-19 2015 (Kansas City, Missouri); 5th Cell & Gene Therapy Conference 19-21 May 2016 (San Antonio, United States); Cell & Gene Therapy Europe 29-30 September 2015 (Barcelona, Spain); Cell Manufacturing and  Gene Therapy Congress 2015 2-3 December 2015 (Brussels, Belgium). 

  • Track 7-1Adoptive immuno therapy
  • Track 7-2Antibodies
  • Track 7-3Gene therapy for HIV positive with cancer
  • Track 7-4Therapeutic vaccines
  • Track 7-5Experimental stem cell gene therapy

Cell therapy approaches for this disease are focused on developing the most efficient methods for the isolation of pancreas beta cells or appropriate stem cells, appropriate location for cell transplant, and improvement of their survival upon infusion. Alternatively, gene and cell therapy scientists are developing methods to reprogram some of the other cells of the pancreas to secrete insulin. Currently ongoing clinical trials using these gene and cell therapy strategies hold promise for improved treatments of type I diabetes in the future. The first gene therapy approach to diabetes was put forward shortly after the cloning of the insulin gene. It was proposed that non-insulin producing cells could be made into insulin-producing cells using a suitable promoter and insulin gene construct, and that these substitute cells could restore insulin production in type 1 and some type 2 diabetics. 

Related Conferences: International Conference on Synthetic Biology, September 28-30, 2015 (Houston, USA); 6th World Congress on Biotechnology, October 05-07, 2015 (New Delhi, India); 3rd International Conference on Genomics & Pharmacogenomics, September 21-23, 2015 (San Antonio, USA); World Bio Summit & Expo, November 02-04, 2015 (Dubai, UAE); International Conference on Genetic Counselling And Genomic Medicine, August 11-12, 2016 (Birmingham, UK); Cell Symposia: Stem Cell Epigenetics 20-22 September 2015 (Barcelona, Spain); EMBO Conference The DNA damage response in cell physiology and disease 5-9 October 2015 (Cape Sounio, Greece); EMBO Conference Nuclear structure and dynamics 7-11 October 2015 (L'Isle-sur-la-Sorgue, France); CSH Asia Mitochondria 12-16 October 2015 (Cold Spring Harbour, New York); ABCAM Chromatin Structure and Function 16-19 November 2015 (Grand Cayman Island).

  • Track 8-1Restoration of insulin secretions
  • Track 8-2Islet transplantation
  • Track 8-3Experimental gene therapy
  • Track 8-4Beta cell replacement strategies
  • Track 8-5Use of stem cells in diabetes gene therapy

Converting a virus into a vector The viral life cycle can be divided into two temporally distinct phases: infection and replication. For gene therapy to be successful, an appropriate amount of a therapeutic gene must be delivered into the target tissue without substantial toxicity. Each viral vector system is characterized by an inherent set of properties that affect its suitability for specific gene therapy applications. For some disorders, longterm expression from a relatively small proportion of cells would be sufficient (for example, genetic disorders), whereas other pathologies might require high, but transient, gene expression. For example, gene therapies designed to interfere with a viral infectious process or inhibit the growth of cancer cells by reconstitution of inactivated tumor suppressor genes may require gene transfer into a large fraction of the abnormal cells.

Related Conferences: International Conference on Clinical And Molecular Genetics, 28-30 November 2016 (Chicago, USA); 6th International Conference on Genomics & Pharmacogenomics, 22-24 September 2016 (Berlin, Germany); World Congress on Human Genetics, 31 October – 02 November 2016 (Valencia, Spain); International Conference on Genetic Counselling And Genomic Medicine, 11-12 August, 2016 (Birmingham, UK); 2nd Cell & Gene Therapy Conference 9-10 September 2015 (Philadelphia, United States); 2015 Midwest Conference on Cell Therapy & Regenerative Medicine September 18-19 2015 (Kansas City, Missouri); 5th Cell & Gene Therapy Conference 19-21 May 2016 (San Antonio, United States); Cell & Gene Therapy Europe 29-30 September 2015 (Barcelona, Spain); Cell Manufacturing and  Gene Therapy Congress 2015 2-3 December 2015 (Brussels, Belgium). 

  • Track 9-1Viral vectors for gene therapy
  • Track 9-2Viral gene therapy
  • Track 9-3Non viral gene therapy

Stem cells have tremendous promise to help us understand and treat a range of diseases, injuries and other health-related conditions. Their potential is evident in the use of blood stem cells to treat diseases of the blood, a therapy that has saved the lives of thousands of children with leukaemia; and can be seen in the use of stem cells for tissue grafts to treat diseases or injury to the bone, skin and surface of the eye. Some bone, skin and corneal (eye) injuries and diseases can be treated by grafting or implanting tissues, and the healing process relies on stem cells within this implanted tissue.  

Related Conferences: International Conference on Clinical And Molecular Genetics, 28-30 November 2016 (Chicago, USA); 6th International Conference on Genomics & Pharmacogenomics, 22-24 September 2016 (Berlin, Germany); World Congress on Human Genetics, 31 October – 02 November 2016 (Valencia, Spain); International Conference on Genetic Counselling And Genomic Medicine, 11-12 August, 2016 (Birmingham, UK); Cell & Gene Therapy Congress, 19-21 May 2016 ( San Antonio, USA); World Stem Cell Summit 10-12 December (Atlanta, Georgia); 2nd International Conference on Stem Cell and Cellular Therapies 15-18 October (Antalya, Turkey); Stem Cell 2016 Summit 27-29 April (Boston, MA); 3rd International Annual Conference of the German Stem Cell Network 9-11 September (Frankfurt); Stem cell Epigenetics 20-22 September (Stiges, Spain).

  • Track 10-1Molecular basis of pleuripotency
  • Track 10-2Bone marrow stem cells as therapy
  • Track 10-3Current views of embryo & Neural stem cells
  • Track 10-4Targeting stem cells for therapeutic benefits
  • Track 10-5Transplantation technologies in stem cell therapy

The ability to preserve the cells is critical to their clinical application. It improves patient access to therapies by increasing the genetic diversity of cells available. In addition, the ability to preserve cells improves the "manufacturability" of a cell therapy product by permitting the cells to be stored until the patient is ready for administration of the therapy, permitting inventory control of products, and improving management of staffing at cell therapy facilities. Finally, the ability to preserve cell therapies improves the safety of cell therapy products by extending the shelf life of a product and permitting completion of safety and quality control testing before release of the product for use. preservation permits coordination between the manufacture of the therapy and patient care regimes.

Related conferences: International Conference on Clinical And Molecular Genetics, 28-30 November 2016 (Chicago, USA); 6th International Conference on Genomics & Pharmacogenomics, 22-24 September 2016 (Berlin, Germany); World Congress on Human Genetics, 31October – 02November 2016 (Valencia, Spain); International Conference on Genetic Counselling And Genomic Medicine, 11-12 August, 2016 (Birmingham, UK); Cell & Gene Therapy Congress, 19-21 May 2016 ( San Antonio, USA); 2015 Midwest Conference on Cell Therapy & Regenerative Medicine September 18-19 2015 (Kansas City, Missouri); 2nd Cell & Gene Therapy Conference 9-10 September 2015 (Philadelphia, United States); Cell & Gene Therapy Europe 29-30 September 2015 (Barcelona, Spain); Cell Manufacturing and  Gene Therapy Congress 2015 2-3 December 2015 (Brussels, Belgium). 

  • Track 11-1Neural stem cells
  • Track 11-2Embryonic stem cells
  • Track 11-3Dental stem cells
  • Track 11-4Stem cells for osteoarthritis
  • Track 11-5Totipotent stem cells

The global stem cell, Stem cell products market will grow from about $5.6 billion in 2013 to nearly $10.6 billion in 2018, registering a compound annual growth rate (CAGR) of 13.6% from 2013 through 2018.This track discusses the implications of stem cell research and commercial trends in the context of the current size and growth of the pharmaceutical market, both in global terms and analysed by the most important national markets

Related Conferences: International Conference on Clinical And Molecular Genetics, 28-30 November 2016 (Chicago, USA); 6th International Conference on Genomics & Pharmacogenomics, 22-24 September 2016 (Berlin, Germany); World Congress on Human Genetics, 31 October – 02 November 2016 (Valencia, Spain); International Conference on Genetic Counselling And Genomic Medicine, 11-12 August, 2016 (Birmingham, UK); 2nd Cell & Gene Therapy Conference 9-10 September 2015 (Philadelphia, United States); 2015 Midwest Conference on Cell Therapy & Regenerative Medicine September 18-19 2015 (Kansas City, Missouri); 5th Cell & Gene Therapy Conference 19-21 May 2016 (San Antonio, United States); Cell & Gene Therapy Europe 29-30 September 2015 (Barcelona, Spain); Cell Manufacturing and  Gene Therapy Congress 2015 2-3 December 2015 (Brussels, Belgium).

  • Track 12-1Stem cell products and analysis in USA & Europe
  • Track 12-2Stem cell research in USA
  • Track 12-3Clinical trails in USA & Europe
  • Track 12-4Cellular therapy in USA & UK

A genetic disease is any disease that is caused by an abnormality in an individual's genome, the person's entire genetic makeup. The abnormality can range from minuscule to major -- from a discrete mutation in a single base in the DNA of a single gene to a gross chromosome abnormality involving the addition or subtraction of an entire chromosome or set of chromosomes. Most genetic diseases are the direct result of a mutation in one gene. However, one of the most difficult problems ahead is to find out how genes contribute to diseases that have a complex pattern of inheritance, such as in the cases of diabetes, asthma, cancer and mental illness. In all these cases, no one gene has the yes/no power to say whether a person has a disease or not. It is likely that more than one mutation is required before the disease is manifest, and a number of genes may each make a subtle contribution to a person's susceptibility to a disease; genes may also affect how a person reacts to environmental factors.

Related Conferences: International Conference on Synthetic Biology, September 28-30, 2015 (Houston, USA); 6th World Congress on Biotechnology, October 05-07, 2015 (New Delhi, India); 3rd International Conference on Genomics & Pharmacogenomics, September 21-23, 2015 (San Antonio, USA); World Bio Summit & Expo, November 02-04, 2015 (Dubai, UAE); International Conference on Genetic Counselling And Genomic Medicine, August 11-12, 2016 (Birmingham, UK); Cell Symposia: Stem Cell Epigenetics 20-22 September 2015 (Barcelona, Spain); EMBO Conference The DNA damage response in cell physiology and disease 5-9 October 2015 (Cape Sounio, Greece); EMBO Conference Nuclear structure and dynamics 7-11 October 2015 (L'Isle-sur-la-Sorgue, France); CSH Asia Mitochondria 12-16 October 2015 (Cold Spring Harbour, New York); ABCAM Chromatin Structure and Function 16-19 November 2015 (Grand Cayman Island).

  • Track 13-1Single gene inheritance/ monogenetic disorders
  • Track 13-2Multifactorial inheritance
  • Track 13-3Chromosome abnormalities

Plants have emerged as powerful production platforms for the expression of fully functional recombinant mammalian proteins. These expression systems have demonstrated the ability to produce complex glycoproteins in a cost-efficient manner at large scale. The full realization of the therapeutic potential of stem cells has only recently come into the forefront of regenerative medicine. Stem cells are unprogrammed cells that can differentiate into cells with specific functions. Regenerative therapies are used to stimulate healing and might be used in the future to treat various kinds of diseases. Regenerative medicine will result in an extended healthy life span. A fresh apple is a symbol for beautiful skin. Hair greying for example could be shown to result from the fact that the melanocyte stem cells in the hair follicle have died off.

Related Conferences: Global Summit on Plant Science, 21-23 September, 2015, (San Antonio, USA); Global Summit on Herbals & Natural Remedies, 26-27 October, 2015, (Chicago, USA); 8th Indo Global Summit And Expo On Vaccines, Therapeutics & Healthcare, 02-04, November, 2015 (Hyderabad, India); 4th International Conference and Exhibition on Probiotics, Functional And Baby Foods 03-05, November, 2015 (Valencia, Spain); 2nd International Conference on Green Energy & Expo, 28-30 November, 2016 (Chicago, USA); 2015 Midwest Conference on Cell Therapy & Regenerative Medicine 18-19 September (Kansas City, Missouri); Keystone Symposia: Molecular and Cellular Basis of Growth and Regeneration 10-11 January (Breckenridge, Colorado); Keystone Symposia – Stem Cells and Regeneration in the Digestive Organs 13-17 ,March (Keystone, Colorado); World Conference on Regenerative Medicine 21-23 October (Leipzig, Germany); 2nd International Congress on Stem Cell and Cellular Therapies 15-18 October (Antalya, Turkey).

  • Track 14-1Stem cell propagation techniques
  • Track 14-2Hormonal therapy with stem cells
  • Track 14-3Plant stem cells & transgenics
  • Track 14-4Genetically modified organisms

As plants cannot escape from danger by running or taking flight, they need a special mechanism to withstand environmental stress. What empowers them to withstand harsh attacks and preserve life is the stem cell. According to Wikipedia, “plant stem cells never undergo the aging process but constantly create new specialized and unspecialized cells, and they have the potential to grow into any organ, tissue, or cell in the body.” The everlasting life is due to the hormones auxin and gibberellin. British scientists found that plant stem cells were much more sensitive to DNA damage than other cells. And once they sense damage, they trigger death of these cells.

Rejuvenate with Plant Stem Cells

Detoxify and release toxins on a cellular level.
Nourish your body with vital nutrients.
Regenerate your cells and diminish the effects of aging.

Related Conferences: Global Summit on Plant Science, 21-23 September, 2015, (San Antonio, USA); Global Summit on Herbals & Natural Remedies, 26-27 October, 2015, (Chicago, USA); 8th Indo Global Summit And Expo On Vaccines, Therapeutics & Healthcare, 02-04, November, 2015 (Hyderabad, India); 4th International Conference and Exhibition on Probiotics, Functional And Baby Foods 03-05, November, 2015 (Valencia, Spain); 2nd International Conference on Green Energy & Expo, 28-30 November, 2016 (Chicago, USA); 2015 Midwest Conference on Cell Therapy & Regenerative Medicine 18-19 September (Kansas City, Missouri); Keystone Symposia: Molecular and Cellular Basis of Growth and Regeneration 10-11 January (Breckenridge, Colorado); Keystone Symposia – Stem Cells and Regeneration in the Digestive Organs 13-17 ,March (Keystone, Colorado); World Conference on Regenerative Medicine 21-23 October (Leipzig, Germany); 2nd International Congress on Stem Cell and Cellular Therapies 15-18 October (Antalya, Turkey).

  • Track 15-1Antiaging therapies
  • Track 15-2Gemmotherapy
  • Track 15-3Multipurpose plant stem cells
  • Track 15-4Stem cell applications in cosmetics longevity
  • Track 15-5Plant extracts & commercial uses
  • Track 15-6New era in plant stem cell technology

clinical trial is a research study that seeks to determine if a treatment is safe and effective. Advancing new cell and gene therapies (CGTs) from the laboratory into early-phase clinical trials has proven to be a complex task even for experienced investigators. Due to the wide variety of CGT products and their potential applications, a case-by-case assessment is warranted for the design of each clinical trial.

Objectives: Determine the pharmacokinetics of this regimen by the persistence of modified T cells in the blood of these patients, Evaluate the immunogenicity of murine sequences in chimeric anti-CEA Ig TCR, Assess immunologic parameters which correlate with the efficacy of this regimen in these patients, Evaluate, in a preliminary manner, the efficacy of this regimen in patients with CEA bearing tumours.

Related Conferences: 4th International Summit On GMP, GCP & Quality Control, 26-28 October, 2015 (Hyderabad, India); 3rd International Conference on Clinical Pharmacy, 07-09 December, 2015 (Atlanta, USA); Pharmaceutical Summit and Expo, 08-10 October, 2015 (New Delhi, India); 3rd International Conference and Exhibition On Pharmacognosy, Phytochemistry& Natural Products, 26-28 October, 2015 (Hyderabad, India); Patient-Centered Clinical Trials 2015 19-20 October 2015 (Le Méridien, Philadelphia); Quantitative Systems Pharmacology 20-22 October 2015 (Boston, MA); Clinical Development and Commercialization of Antibacterial  22-23 September 2015 (Boston, MA); Summit for Clinical Ops Executives 23-25 February 2016( Miami, FL); Clinical IT Strategy and Governance 23-25 February 2016 (Miami, FL).

  • Track 16-1Principles of gene therapy & clinical gene therapy
  • Track 16-2Animal & human trails of engineered tissues
  • Track 16-3Emerging clinical aspects of stem cell technologies
  • Track 16-4Pharmacogenomics in cell therapy
  • Track 16-5Clinical trial design & analysis
  • Track 16-6Clinical genetics
  • Track 16-7Alternative lab models for therapeutic applications

Epigenetics is the study of heritable changes in the phenotype of a cell or organism that are not caused by its genotype. The molecular basis of an epigenetic profile arises from covalent modifications of protein and DNA components of chromatin. The epigenetic profile of a cell often dictates cell fate, as well as mammalian development, aging and disease. Epigenetics has evolved to become the science that explains how the differences in the patterns of gene expression in diverse cells or tissues are executed and inherited.

Related Conferences: International Conference on Synthetic Biology, September 28-30, 2015 (Houston, USA); 6th World Congress on Biotechnology, October 05-07, 2015 (New Delhi, India); 3rd International Conference on Genomics & Pharmacogenomics, September 21-23, 2015 (San Antonio, USA); World Bio Summit & Expo, November 02-04, 2015 (Dubai, UAE); International Conference on Genetic Counselling And Genomic Medicine, August 11-12, 2016 (Birmingham, UK); Cell Symposia: Stem Cell Epigenetics 20-22 September 2015 (Barcelona, Spain); EMBO Conference The DNA damage response in cell physiology and disease 5-9 October 2015 (Cape Sounio, Greece); EMBO Conference Nuclear structure and dynamics 7-11 October 2015 (L'Isle-sur-la-Sorgue, France); CSH Asia Mitochondria 12-16 October 2015 (Cold Spring Harbour, New York); ABCAM Chromatin Structure and Function 16-19 November 2015 (Grand Cayman Island).

  • Track 17-1Cell based immunotherapy
  • Track 17-2Cancer immune cells
  • Track 17-3Cell based immuno suppression in transplantation
  • Track 17-4New cell therapies for allergies
  • Track 17-5Tumor cells evade or defeat immune system

The goals of bioengineering strategies for targeted cancer therapies are (1) to deliver a high dose of an anticancer drug directly to a cancer tumour, (2) to enhance drug uptake by malignant cells, and (3) to minimize drug uptake by non-malignant cells. In ESRD micro electro mechanical systems and nanotechnology to create components such as robust silicon Nano pore filters that mimic natural kidney structure for high-efficiency toxin clearance. It also uses tissue engineering to build a miniature bioreactor in which immune-isolated human-derived renal cells perform key functions, such as reabsorption of water and salts. In drug delivery for a leading cause of blindness, photo-etching fabrication techniques from the microchip industry to create thin-film and planar micro devices (dimensions in millionths of meters) with protective medication reservoirs and nanopores (measured in billionths of meters) for insertion in the back of the eye to deliver sustained doses of drug across protective retinal epithelial tissues over the course of several months.

Related Conferences: International Conference On Protein Engineering, 26-28 October, 2015 (Chicago, USA); 4th International Conference and Exhibition on Biometrics & Biostatistics, 16-18 November, 2015 (San Antonio, USA); 4th International Conference and Exhibition On Biosensors & Bioelectronics, 28-30 September, 2015 (Atlanta, USA); International Conference and Business Expo On Wireless Communication & Network, 21-23 September, 2015 (Baltimore, USA); Global Summit on Electronics And Electrical Engineering, 03-05 November, 2015 (Valencia, Spain); International Conference on Medical Devices, 21-22 September, 2015 (Florida, USA); 2015 International Conference on Manufacturing and Optimization 15-16 September 2015(Singapore); Imaging: Recent Advances and Biomedical Applications 30th September (London, United Kingdom); Singapore Health & Biomedical Congress 2015 2-3 October 2015 (Singapore ); VECCOMAS Thematic Conferences on Computational Vision and Medical Image Processing Tenerife 19-21 October 2015(Spain); Protein & Antibody Engineering Summit 2-6 November 2015(Lisbon, Portugal).

  • Track 18-1Biomedical engineering
  • Track 18-2Developing new probes for tissue targeting
  • Track 18-3Therapeutic bioengineering
  • Track 18-4Cellular mechanobiology
  • Track 18-5Tissue engineering for own stem cells
  • Track 18-6Current understanding & challenges in bioprocessing
  • Track 18-7Bio engineering for medical diagnostic & imaging

Advanced therapies are different from conventional medicines, which are made from chemicals or proteins. Gene-therapy medicines: these contain genes that lead to a therapeutic effect. They work by inserting 'recombinant' genes into cells, usually to treat a variety of diseases, including genetic disorders, cancer or long-term diseases. Somatic-cell therapy medicines: these contain cells or tissues that have been manipulated to change their biological characteristics. Advanced Cell & Gene Therapy provides guidance in process development, GMP/GTP manufacturing, regulatory affairs, due diligence and strategy, specializing in cell therapy, gene therapy, and tissue-engineered regenerative medicine products.

Related Conferences: International Conference on Clinical And Molecular Genetics, 28-30 November 2016 (Chicago, USA); 6th International Conference on Genomics & Pharmacogenomics, 22-24 September 2016 (Berlin, Germany); World Congress on Human Genetics, 31October – 02November 2016 (Valencia, Spain); International Conference on Genetic Counselling And Genomic Medicine, 11-12 August, 2016 (Birmingham, UK); Cell & Gene Therapy Congress, 19-21 May 2016 ( San Antonio, USA); 2015 Midwest Conference on Cell Therapy & Regenerative Medicine September 18-19 2015 (Kansas City, Missouri); 2nd Cell & Gene Therapy Conference 9-10 September 2015 (Philadelphia, United States),; Cell & Gene Therapy Europe 29-30 September 2015 (Barcelona, Spain); Cell Manufacturing and Gene Therapy Congress 2015 2-3 December 2015 (Brussels, Belgium).

  • Track 19-1Tumor suppressor genes
  • Track 19-2Bio markers involved in gene therapy
  • Track 19-3Genetic screening and diagnostics
  • Track 19-4Cloning & expression systems
  • Track 19-5Mobile genetic elements
  • Track 19-6Vectors of gene therapy
  • Track 19-7Cellular & organismal genetic engineering
  • Track 19-8Gene transfer to induce cellular programming
  • Track 19-9Therapies for genetic disorders/ autoimmune diseases

Gene therapy involves making changes to the body’s set of basic instructions, it raises many unique ethical concerns. Current gene therapy research has focused on treating individuals by targeting the therapy to body cells such as bone marrow or blood cells. This type of gene therapy cannot be passed on to a person’s children. Gene therapy could be targeted to egg and sperm cells. Stem Cell Research offers great promise for understanding basic mechanisms of human development and differentiation, as well as the hope for new treatments for diseases such as diabetes, spinal cord injury, Parkinson’s disease, and myocardial infarction. Pluripotent stem cells perpetuate themselves in culture and can differentiate into all types of specialized cells. Scientists plan to differentiate pluripotent cells into specialized cells that could be used for transplantation.

Related Conferences: International Conference on Clinical And Molecular Genetics, 28-30 November 2016 (Chicago, USA); 6th International Conference on Genomics & Pharmacogenomics, 22-24 September 2016 (Berlin, Germany); World Congress on Human Genetics, 31October – 02November 2016 (Valencia, Spain); International Conference On Genetic Counselling And Genomic Medicine, 11-12 August, 2016 (Birmingham, UK); Cell & Gene Therapy Congress, 19-21 May 2016 ( San Antonio, USA); 2015 Midwest Conference on Cell Therapy & Regenerative Medicine September 18-19 2015 (Kansas City, Missouri); 2nd Cell & Gene Therapy Conference 9-10 September 2015 (Philadelphia, United States); Cell & Gene Therapy Europe 29-30 September 2015 (Barcelona, Spain); Cell Manufacturing and  Gene Therapy Congress 2015 2-3 December 2015 (Brussels, Belgium). 

  • Track 20-1Commercialization strategy
  • Track 20-2Ethics involved in human stem cells
  • Track 20-3Logistics involved in lab models for cell therapy applications
  • Track 20-4Innovative therapeutic technologies
  • Track 20-5Manufacturing of cell therapy products & marketing
  • Track 20-6FDA & EMA guidelines